Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.
Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates
Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.